Michael Staun

Michael Staun

Clinical Associate Professor

Member of:

  • Internal Medicine: Gastroenterology and Hepatology


Publication year:
All
1 - 2 out of 2Page size: 10
  1. 2022
  2. Published

    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    Peyrin-Biroulet, L., Hart, A., Bossuyt, P., Long, M., Allez, M., Juillerat, P., Armuzzi, A., Loftus, E. V., Ostad-Saffari, E., Scalori, A., Oh, Y. S., Tole, S., Chai, A., Pulley, J., Lacey, S., Sandborn, W. J., Aguilar, H., Ahmad, T., Akriviadis, E., Aldeguer Mante, X. & 31 others, Altorjay, I., Ananthakrishnan, A., Andersen, V., Andreu Garcia, M., Aumais, G., Avni-Biron, I., Axler, J., Ayub, K., Baert, F., Bafutto, M., Bamias, G., Bassan, I., Baum, C., Beaugerie, L., Behm, B., Bekal, P., Bennett, M., Bermejo San Jose, F., Bernstein, C., Bettenworth, D., Bhaskar, S., Biancone, L., Bilir, B., Blaeker, M., Bloom, S., Bohman, V., Bosques Padilla, F. J., Bouhnik, Y., Seidelin, Jakob Benedict, Staun, Michael & HICKORY Study Group, H. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 2, p. 128-140 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

    Vermeire, S. & LAUREL Study Group, L. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 1, p. 28-37 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 922882